Edukasi SEGAR untuk Pencegahan ISPA di Rusunawa Selagalas Mataram
Medical Community Dedication · 10.12.2025 · 1 (2) · 43-49
DOI: 10.36679/jmcd.v1i2.10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Community Dedication, online erschienen am 10.12.2025. Verfasst von Musyarrafah und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Acute Respiratory Infection (ARI) is a major health issue in Rusunawa Selagalas, driven by inadequate ventilation and smoking behavior. The objective of this community service, to identify priority health problems, analyze major risk factors, and implement an educational intervention (“SEGAR”) to reduce ARI risk. Community diagnosis was conducted through direct observation, structured questionnaires (n=91), and priority setting using the Delbecq method with resident participation. Main variables included ventilation, smoking, and ARI incidence. Descriptive (univariate) analysis was performed. ARI was reported in 80.22% of residents, with poor ventilation and smoking as dominant risk factors. The SEGAR education program improved awareness of ventilation hygiene and smoking hazards. Community-based education combined with basic housing improvements is effective in mitigating ARI risk in dense housing. Sustained collaboration between residents, housing managers, and local government is recommended.
Zitieren
APA
Musyarrafah, & Sahrun (2025). Edukasi SEGAR untuk Pencegahan ISPA di Rusunawa Selagalas Mataram. Medical Community Dedication, 1(2), 43-49. https://doi.org/10.36679/jmcd.v1i2.10
Vancouver
Musyarrafah, Sahrun. Edukasi SEGAR untuk Pencegahan ISPA di Rusunawa Selagalas Mataram. Medical Community Dedication. 2025;1(2):43-49. doi:10.36679/jmcd.v1i2.10
BibTeX
@article{Musyarrafah2025,
author = {Musyarrafah and Sahrun},
title = {Edukasi SEGAR untuk Pencegahan ISPA di Rusunawa Selagalas Mataram},
journal = {Medical Community Dedication},
year = {2025},
volume = {1},
number = {2},
pages = {43--49},
doi = {10.36679/jmcd.v1i2.10}
}
EUVIMED